Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. To date, results suggest that hematologic events are severe but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less severe than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications and combinations by two routes of administration.

In addition to the Phase 2 clinical trial in CRC, Poniard is currently evaluating the efficacy and safety of picoplatin in small cell lung cancer in a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009. Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with castration-resistant (or hormone-refractory) prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of clinical trials, business objectives and strategic goals, drug developme
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 Insights- ... seamlessly connects people, technologies and care protoc ols across ... and the cost of healthcare delivery   ... presence at  ESC Congress 2015 , where the company is ... EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology with ...
(Date:8/27/2015)... Aug. 27, 2015 Biosimilars are not ... the U.S. Food and Drug Administration (FDA) for ... in its draft guidance issued today. The FDA,s ... proposes distinguishable names, calling for biological products to ... suffix. This proposal reflects the agency,s thinking that ...
(Date:8/27/2015)... , Aug. 27, 2015   Women Grow , the fastest-growing ... is partnering with the Cannabis World Congress & Business ... to produce 15 business-focused educational sessions. CWCBExpo in LA will ... Angeles Convention Center in Los Angeles, ... the West Coast for the marijuana industry. The ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
(Date:8/28/2015)... ... August 28, 2015 , ... ... Devices:, Understanding the FDA’s Position and Best Practices for Compliance, **Presented by ... , This workshop, chaired by internationally renowned expert Fubin Wu, has been ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in ... Foundation has added yet another accolade to its cadre of widespread support—an official letter ... “With the help of the medical community and the University of Illinois at Chicago’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ... might personally be struggling with chemical dependency, may be able to find some ... a results-driven holistic treatment center for addiction located in Western Michigan. Focusing on ...
(Date:8/28/2015)... ... 2015 , ... “ Frequentz ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... businesses to track product movement from beginning to end. , Businesses benefit greatly from ...
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and alcohol abuse by ... a new approach on solutions in his new book ":Unraveling The Psychological Mystery ... getting together for meaningful group meetings. "This would educate the employees on not ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... think that picking and eating apples this time of year ... America’s favorite fruit, you may want to think again. //Apples ... anyone could add to their diet, finds a collection of ... at the Society of Neuroscience annual conference in Atlanta. Researchers ...
... but a microsensor created by University of Alberta engineers may ... recovering from hip replacement surgery. //The U of A research ... bone healing process after surgery—it is so tiny it can ... not only reduces post-operation recovery time, it will also help ...
... School of Medicine in St. Louis have helped usher in ... //Using radiofrequency devices — rather than a scalpel — ... to perform. ,"Because of the devices, the procedure — ... that hardly anyone was doing to one that 80 to ...
... bottlers’ claim of reduced risk of dental caries or tooth ... Dental Association (ADA). // ,"Whether you drink fluoridated water ... doing the right thing for your oral health," says ADA ... decision, bottlers can now claim what dentists have long known--that ...
... According to a countrywide study conducted by Queensland University ... old, fear the danger of violence than old age. ... Study, //revealed the need of women to protect themselves ... Professor Jan Lovie-Kitchin, from the Faculty of Health, said ...
... was very little significant difference found with respect to ... during C-section. Some women, however had lower blood ... and some experienced more nausea and vomiting with regional ... to consider both neonatal and maternal outcomes related to ...
Cached Medicine News:Health News:Pick Apples for Good Neurological Health, Says New Research 2Health News:New Biomedical Device to Monitor Hip Implant Healing 2Health News:High-Energy Clamp Simplifies Heart Surgery for Atrial Fibrillation 2Health News:High-Energy Clamp Simplifies Heart Surgery for Atrial Fibrillation 3Health News:Fear of violence among older women 2Health News:Choice of Anesthesia in C-section 2Health News:Choice of Anesthesia in C-section 3
... is a freestanding cryostat with a ... and a radial cutting microtome. It ... wide range of specimens and materials ... in high biohazard risk laboratories where ...
The HM 550 series is a uniquely progressive concept for use with frozen specimens of all types. User applications define module selection and make even serial sectioning enjoyable....
... TP1020 product family are semi-enclosed tissue processors. ... of approved technology with modern and functionally ... safety for tissues at all stages of ... on proven precision mechanics in conjunction with ...
The HMP300 Histo Pro delivers all the features and benefits that conventional tissue processing have to offer....
Medicine Products: